Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer-Reference-Cited by-同舟云学术

Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer

Published:2020-10-26 Issue:12 Volume:36 Page:2025-2036
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Chabot Isabelle¹²,Zhao Qi²,Su Yun³

Affiliation:

1. Faculty of Pharmacy, Montreal University, Montreal, Quebec, Canada

2. Global Value & Access, Eisai Inc., Woodcliff Lake, NJ, USA

3. Formerly of Global Value & Access, Eisai Inc., Woodcliff Lake, NJ, USA

Funder

Eisai Inc., Woodcliff Lake, NJ, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1835853

Reference53 articles.

1. Metastatic breast cancer; 2019. Available from: https://www.breastcancer.org/symptoms/types/recur_metast.

2. O’Shaughnessy JJTo. Extending survival with chemotherapy in metastatic breast cancer. 2005;10(Supplement 3):20–29.

3. Breast cancer

4. National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer Stat Facts: Female Breast Cancer (SEER 18 2010-2016). Available from: https://seer.cancer.gov/statfacts/html/breast.html.

5. AC Society. Breast cancer facts & figures 2017–2018: Atlanta: American Cancer Society, Inc; 2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprietary Synthesis of the C27–C35 Fragment of Eribulin and Its Elaboration toward the C14–C35 Subunit;Organic Process Research & Development;2024-06-28

2. A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer;Journal of Comparative Effectiveness Research;2024-06

3. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer;Breast Cancer Research and Treatment;2024-02-04

4. Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting;Chemotherapy;2022-09-15

5. A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B;Proceedings of the National Academy of Sciences;2022-08-05